Morgan Stanley
CDAK

Morgan Stanley’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Morgan Stanley’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,334
Closed -$2.67K – 7831
2023
Q1 		$2.67K Sell
15,334
-1,717
-10% -$956 ﹤0.01% 7186
2022
Q4 		$6.78K Sell
17,051
-16,048
-48% -$10.6K ﹤0.01% 7066
2022
Q3 		$26K Buy
33,099
+1,493
+5% +$3.13K ﹤0.01% 6683
2022
Q2 		$90K Buy
31,606
+7,147
+29% +$25.1K ﹤0.01% 6334
2022
Q1 		$153K Buy
24,459
+1,932
+9% +$12.1K ﹤0.01% 6065
2021
Q4 		$251K Sell
22,527
-9,920
-31% -$138K ﹤0.01% 5947
2021
Q3 		$529K Buy
32,447
+4,229
+15% +$75.7K ﹤0.01% 5459
2021
Q2 		$523K Sell
28,218
-772
-3% -$14.8K ﹤0.01% 5495
2021
Q1 		$437K Sell
28,990
-1,512
-5% -$32.9K ﹤0.01% 5230
2020
Q4 		$986K Buy
+30,502
New +$403K ﹤0.01% 4676

Morgan Stanley's CDAK Position: Q2 2023 in Review

Morgan Stanley sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 15,334 shares — an estimated $2.67K sold.

Morgan Stanley first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $986K in Q4 2020. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Morgan Stanley reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Morgan Stanley sold 15,334 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $2.67K.
  • Morgan Stanley first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Morgan Stanley's Codiak BioSciences, Inc. Common Stock position peaked at $986K in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.